美股異動丨Arvinas盤前漲近4% 與輝瑞將vepdegestrant的商業化權利對外轉授權
Arvinas(ARVN.US)盤前漲3.81%報7.9美元;輝瑞(PFE.US)盤前漲0.75%。消息面上,Arvinas及輝瑞已決定將重磅創新藥vepdegestrant的商業化權利對外轉授權,該藥是一種用於乳腺癌的在研雌激素受體蛋白降解劑(乳腺癌ER降解劑)。其批準申請已於6月提交美國食品藥品監督管理局(FDA)。Arvinas表示,鑑於vepdegestrant項目的重大變更,該公司將裁員15%,尋求更大的戰略性業務發展機遇,並識別更多提效空間。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.